SEC Tracker
Get the app

Celsion IMNN

Celsion FY 2021: revenue $500K, flat

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Celsion reported for the year ended Dec 31, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$500KFlat against $500K in FY 202010-K income statement, on EDGAR
  2. Net income−$20.8MAgainst −$21.5M in FY 202010-K income statement, on EDGAR
  3. Cash and cash equivalents$19.6M+14% from $17.2M in FY 2020Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  4. Cash from operations−$16.2MAgainst −$15.6M in FY 202010-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Celsion files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Armata Pharmaceuticals ARMP public float $21M, Jun 30, 2025
  2. Lunai Bioworks LNAI public float $21M, Dec 31, 2025
  3. Dare Bioscience DARE public float $21M, Jun 30, 2025
  4. Fibrogen FGEN public float $21M, Jun 30, 2025
  5. Aptose Biosciences APTOF public float $22M, Jun 28, 2025